Specifically, in 2021-2023, Moderna invested proceeds from its pandemic-era vaccine sales into building a diverse pipeline and established the market for its COVID-19 vaccine, Spikevax®. In ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 ...
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...
The Centers for Disease Control and Prevention says that the Federal Drug Administration has ended a program that provided ...
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...